Results: 7

Anti-PD-1 and anti-PD-l1 antibodies as immunotherapy against cancer: a structural perspective

Rev. invest. clín; 73 (1), 2021
ABSTRACT Programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand-1 (PD-L1), play key roles in the suppression of the cytotoxic activity of T cells. PD-L1 is overexpressed on various types of cancer cells, leading to immune evasion. In the past decade, therapeutic antibodies that ta...

Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study

J. bras. pneumol; 47 (4), 2021
ABSTRACT Objective: EBUS-TBNA cytological sampling is routinely performed for pathological diagnosis, mediastinal staging, and molecular testing in lung cancer patients. EBUS-TBNA samples are not formally accepted for testing programmed death-ligand 1 (PD-L1) expression. The objective of the study was t...

Immunotherapy treatment against cervical cancer

Rev. invest. clín; 72 (4), 2020
ABSTRACT Cervical cancer (CC) is one of the most common gynecological tumors and an important health problem, especially in developing countries. The vast majority of patients in early stages are cured of the disease with surgical treatment and with concomitant chemoradiotherapy in locally advanced stage...

Análise imunoistoquímica da expressão de PD-L1 em células tumorais e células T nos carcinomas de células escamosas do pênis

Introdução: A neoplasia do pênis é uma doença rara, sendo mais frequente nos países em desenvolvimento. Representa 0,4%dos tumores malignos dos homens nos EUA e 2,1% no Brasil, sendo mais prevalente nas regiões norte e nordeste. O carcinoma epidermóide representa aproximadamente 95% das neoplasia...

Molecular profile of non-small cell lung cancer in northeastern Brazil

J. bras. pneumol; 45 (3), 2019
ABSTRACT Objective: To investigate the histological subtypes and mutational profiles of non-small cell lung cancer in Brazil, looking for correlations among histological subtypes, expression of anaplastic lymphoma kinase (ALK), EGFR mutation status, and programmed death-ligand 1 (PD-L1) expression. Met...

PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension

Braz. j. med. biol. res; 51 (8), 2018
Pregnancy-induced hypertension (PIH) causes significant maternal and fetal morbidity and mortality. A decreased number of regulatory T (Treg) cells is associated with the pathogenesis of PIH. The programmed cell death-1 (PD-1)/PD-ligand 1 (PD-L1) pathway is critical to normal pregnancy (NP) by promoting ...

Metastatic Lymphoepithelioma-like Hepatocellular Carcinoma: a Potential Diagnostic Pitfall and Demonstration of Pd-l1 Expression

Ann. hepatol; 16 (1), 2017
Abstract: Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is a rare primary hepatic neoplasm with female predominance and relatively good prognosis. We report a 73-year-old female with chronic hepatitis B who developed metastatic lesions 5 years after underwent resection for LEL-HCC. The metast...